REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Signing of Strategic Platform License

MaxCyteAnnouncement

30/01/2024 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240130:nRSd3812Ba&default-theme=true

RNS Number : 3812B  MaxCyte, Inc.  30 January 2024

 

 

 

 

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of
Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic,
Off-the-Shelf Cell Therapies for Cancers

 

Wugen to use MaxCyte's Flow Electroporation® technology and ExPERT™
platform to support its programs for hematologic and solid tumor cancers

 

ROCKVILLE, MD, and ST LOUIS, MO, Jan. 30, 2024 - MaxCyte, Inc.
(https://maxcyte.com/) , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering
focused company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation cell-based
therapeutics and innovative bioprocessing applications, and Wugen, Inc., a
clinical-stage biotechnology company developing allogeneic, off-the-shelf cell
therapies to treat a broad range of hematological and solid tumor
malignancies, today announced the signing of a strategic platform license
(SPL).

 

Under the terms of the agreement, Wugen gains non-exclusive clinical and
commercial rights to use MaxCyte's Flow Electroporation® technology and
ExPERT™ platform. In return, MaxCyte will receive annual license fees and
program-related revenue.

 

Wugen is developing the next generation of off-the-shelf memory natural killer
(NK) and CAR-T cell therapies for cancer.  The company's investigational cell
therapies originate from healthy donors and are further engineered to enhance
their function of eliminating cancer cells. Wugen's lead program is evaluating
WU-CART-007, a CD7 targeted CAR-T cell therapy, in a global Phase 1/2 clinical
trial for the treatment of relapsed or refractory (R/R) T-cell acute
lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL) in adolescent and
adult patients. WU-CART-007 has received Orphan Drug, Fast Track, and Rare
Pediatric Disease Designations from the U.S. Food and Drug Administration for
the treatment of R/R T-ALL/LBL. Additional information is available on
clinicaltrials.gov, identifier NCT# 04984356.

 

"As WU-CART-007 is transferred onto the ExPERT platform and continues to
progress in the clinic, we are able to support efficient and seamless
expansion to large-scale manufacturing," said Maher Masoud, President and CEO
of MaxCyte. "By working with MaxCyte, Wugen can maximize the number of doses
in each manufacturing run for later stage clinical development and potential
commercial phase."

 

"Our partnership with MaxCyte is an exciting step in advancing our
groundbreaking therapies for difficult-to-treat cancers," said Kumar
Srinivasan, PhD, MBA, President and CEO of Wugen. "This collaboration brings
us even closer to delivering life-saving treatments to patients with limited
options. With MaxCyte's expertise, we're in a position to expedite progress
through crucial development stages and make a significant impact on patients'
lives."

 

MaxCyte's ExPERT™ instrument portfolio represents the next generation of
clinically validated electroporation technology for complex and scalable cell
engineering. Offering high transfection efficiency, seamless scalability, and
enhanced functionality, the ExPERT™ platform is crucial for enabling the
next wave of biological and cellular therapeutics. Wugen is MaxCyte's 26(th)
clinical/commercial partnership overall, each of which generates
pre-commercial milestone revenue, the vast majority of which includes
sales-based payments.

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com (https://maxcyte.com/) and follow us on X
(https://twitter.com/MaxCyte_info) (formerly Twitter) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

About Wugen

 

Wugen, Inc. is a clinical-stage biotechnology company developing the next
generation of off-the-shelf memory natural killer (NK) and CAR-T cell
therapies for cancer. Wugen is leveraging its proprietary Moneta™ platform
and deep genomic engineering expertise to pioneer a new class of memory NK
cell therapies to treat hematological and solid tumor malignancies. For more
information, please visit https://wugen.com/ (https://wugen.com/)

 

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Seismic Collaborative

Valerie Enes

+1 408-497-8568

venes@spectrumscience.com (mailto:venes@spectrumscience.com)

 

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 

Wugen Contacts:

 

Investor Contact

Mark Lewis

+1 314-501-1968

Mlewis@wugen.com

 

Media Contact

Christine Fanelle

Scient PR

+1 215-595-5211

christine@scientpr.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBMMMTMTJJBJI